

## MODERN UNDERSTANDING OF THE ETIOPATHOGENESIS OF ACUTE CEREBROVASCULAR ACCIDENTS AND THEIR IMPACT ON LIVER FUNCTION.

**Kholboeva Gulnoz Bakhadirovna**

Anesthesiologist-resuscitator Ministry of Health

Republic of Uzbekistan City Clinical Hospital Ambulance Medical Care,

**Abstract:** Acute cerebrovascular accidents (CVAs) remain a leading cause of morbidity and mortality worldwide. This paper reviews the modern understanding of the etiopathogenesis of CVAs, emphasizing the ischemic and hemorrhagic types. Additionally, the article explores the impact of CVAs on liver function, highlighting the multifaceted interactions between cerebral and hepatic systems. The need for interdisciplinary approaches in managing CVA patients and future research directions are also discussed.

**Keywords:** Acute cerebrovascular accidents (CVAs), Stroke, Ischemic stroke, Hemorrhagic stroke, Etiopathogenesis, Hypoxia, Hypoperfusion, Inflammatory response, Metabolic disruptions, Liver function

Cerebrovascular accidents, commonly known as strokes, are acute disruptions of cerebral blood flow resulting in neurological deficits. Strokes are classified into two main types: ischemic and hemorrhagic. The etiopathogenesis of these conditions involves complex mechanisms including thromboembolism, vascular rupture, inflammation, and oxidative stress. Understanding these mechanisms is crucial for developing effective prevention and treatment strategies.

With the accelerated aging of the population, ischemic stroke has become a heavy disease burden worldwide. Acute brain ischemia leads to a series of alterations in the immune system, the hypothalamic–pituitary–adrenal axis, and the autonomic nervous system, which negatively affect peripheral organs and contribute to ischemic brain injury development. Emerging research highlights a bidirectional communication between the brain and liver, as evidenced by changes in hepatic glucose metabolism, bilirubin, and liver enzyme levels in the early stages of an ischemic stroke, which subsequently influence stroke prognosis. To uncover novel stroke treatments, recent clinical studies have focused on the relationship between poststroke liver serological markers and cerebral infarction severity and prognosis, exploring the therapeutic potential of “treating the liver to reduce brain

damage.” Etiopathogenesis of CVA ischemic Stroke. Ischemic stroke, accounting for approximately 87% of all strokes, occurs due to the obstruction of blood vessels supplying the brain. The primary mechanisms include:

- Thrombosis: Formation of a blood clot within a cerebral artery.
- Embolism: Migration of a clot from another part of the body to the brain.
- Systemic hypoperfusion: Reduced blood flow due to cardiac failure or severe hypotension.

Pathophysiological changes include hypoxia, cellular energy failure, and excitotoxicity, leading to neuronal injury and death. Hemorrhagic Stroke. Hemorrhagic stroke results from the rupture of a blood vessel within the brain, leading to bleeding and increased intracranial pressure. Key factors include:

- Hypertension: Chronic high blood pressure weakens blood vessel walls.
- Aneurysms: Abnormal bulging of arterial walls that can rupture.
- Arteriovenous malformations: Congenital defects in the vascular structure.

The resulting hematoma causes mechanical damage and disrupts normal cerebral metabolism.

Impact of CVAs on Liver Function. Hypoxia and Hypoperfusion. During and after a CVA, systemic blood flow may be compromised, potentially leading to hepatic hypoxia and reduced liver perfusion. This can impair liver function, affecting its ability to metabolize substances and produce essential proteins. Inflammatory Response. A systemic inflammatory response is often triggered by a CVA, involving the release of cytokines and other inflammatory mediators. This can extend beyond the central nervous system, affecting liver function and possibly causing hepatocellular damage.

Metabolic Disruptions. CVAs can lead to metabolic disturbances, including alterations in glucose and lipid metabolism. The liver, being central to these processes, may exhibit functional impairments, which can complicate the clinical picture and affect recovery.

Medication Effects. Pharmacological treatments for CVAs, such as anticoagulants, thrombolytics, and neuroprotective agents, may have hepatotoxic effects. Monitoring liver function during and after such treatments is crucial to avoid additional complications. Relevance and Future Directions Prevalence and Public Health Impact. Strokes are a major public health concern due to their high incidence and the severe disability they often cause. The interaction between stroke and liver function underscores the importance of a holistic approach to patient care.

Interdisciplinary Approaches. Effective management of CVA patients requires a multidisciplinary team, including neurologists, hepatologists, cardiologists, and rehabilitation specialists. This collaborative approach ensures comprehensive care, addressing both cerebral and hepatic health. Research and Development. Future research should focus on elucidating the precise mechanisms of cerebro-hepatic interactions during and after a CVA. Understanding these pathways may lead to the development of targeted therapies that protect both brain and liver function.

### Conclusion

The modern understanding of the etiopathogenesis of CVAs and their impact on liver function highlights the complexity of stroke pathology and the importance of considering systemic effects. Interdisciplinary approaches and continued research are essential for improving outcomes for stroke patients and addressing the multifaceted nature of this condition.

### REFERENCES

1. Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., & Marsh, E. E. (1993). Classification of subtype of acute ischemic stroke. \*Definitions for use in a multicenter clinical trial\*. TOAST. \*Trial of Org 10172 in Acute Stroke Treatment\*. Stroke, 24(1), 35-41.
2. Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., ... & Muntner, P. (2018). Heart disease and stroke statistics—2018 update: a report from the American Heart Association. \*Circulation\*, 137(12), e67-e492.
3. Feigin, V. L., Norrving, B., & Mensah, G. A. (2017). Global burden of stroke. \*Circulation research\*, 120(3), 439-448.
4. Mann, J. D., Hankey, G. J., & Eikelboom, J. W. (2007). The role of antithrombotic therapy in stroke prevention. \*European Journal of Neurology\*, 14(5), 461-474.